Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Other Non-Current Liabilities: 2020-2022

Historic Other Non-Current Liabilities for Kymera Therapeutics (KYMR) over the last 3 years, with Dec 2022 value amounting to $248,000.

  • Kymera Therapeutics' Other Non-Current Liabilities fell 96.88% to $8,000 in Q3 2023 from the same period last year, while for Sep 2023 it was $8,000, marking a year-over-year decrease of 96.88%. This contributed to the annual value of $248,000 for FY2022, which is 275.76% up from last year.
  • Per Kymera Therapeutics' latest filing, its Other Non-Current Liabilities stood at $248,000 for FY2022, which was up 275.76% from $66,000 recorded in FY2021.
  • Over the past 5 years, Kymera Therapeutics' Other Non-Current Liabilities peaked at $248,000 during FY2022, and registered a low of $66,000 during FY2021.
  • Moreover, its 3-year median value for Other Non-Current Liabilities was $100,000 (2020), whereas its average is $138,000.
  • In the last 5 years, Kymera Therapeutics' Other Non-Current Liabilities slumped by 34.00% in 2021 and then soared by 275.76% in 2022.
  • Yearly analysis of 3 years shows Kymera Therapeutics' Other Non-Current Liabilities stood at $100,000 in 2020, then tumbled by 34.00% to $66,000 in 2021, then spiked by 275.76% to $248,000 in 2022.